Sutro Biopharma Inc (STRO)
4.28
+0.03
(+0.71%)
USD |
NASDAQ |
May 08, 16:00
4.29
+0.01
(+0.23%)
After-Hours: 20:00
Sutro Biopharma Enterprise Value: -42.34M for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | -42.34M |
| May 07, 2024 | -44.64M |
| May 06, 2024 | -72.34M |
| May 03, 2024 | -76.95M |
| May 02, 2024 | -68.49M |
| May 01, 2024 | -83.87M |
| April 30, 2024 | -110.41M |
| April 29, 2024 | -100.80M |
| April 26, 2024 | -108.49M |
| April 25, 2024 | -108.49M |
| April 24, 2024 | -104.64M |
| April 23, 2024 | -85.41M |
| April 22, 2024 | -81.57M |
| April 19, 2024 | -92.33M |
| April 18, 2024 | -81.57M |
| April 17, 2024 | -79.26M |
| April 16, 2024 | -68.49M |
| April 15, 2024 | -53.11M |
| April 12, 2024 | -53.11M |
| April 11, 2024 | -25.41M |
| April 10, 2024 | -45.41M |
| April 09, 2024 | -33.88M |
| April 08, 2024 | -6.953M |
| April 05, 2024 | 3.816M |
| April 04, 2024 | 6.893M |
| Date | Value |
|---|---|
| April 03, 2024 | -53.73M |
| April 02, 2024 | -53.73M |
| April 01, 2024 | -39.05M |
| March 28, 2024 | -18.76M |
| March 27, 2024 | -63.72M |
| March 26, 2024 | -110.55M |
| March 25, 2024 | -167.37M |
| March 22, 2024 | -158.01M |
| March 21, 2024 | -153.63M |
| March 20, 2024 | -159.25M |
| March 19, 2024 | -154.97M |
| March 18, 2024 | -133.01M |
| March 15, 2024 | -120.81M |
| March 14, 2024 | -126.91M |
| March 13, 2024 | -93.35M |
| March 12, 2024 | -101.28M |
| March 11, 2024 | -99.45M |
| March 08, 2024 | -86.64M |
| March 07, 2024 | -78.71M |
| March 06, 2024 | -84.81M |
| March 05, 2024 | -94.57M |
| March 04, 2024 | -79.32M |
| March 01, 2024 | -69.56M |
| February 29, 2024 | -72.00M |
| February 28, 2024 | -61.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-221.84M
Minimum
Nov 13 2023
916.42M
Maximum
Jan 22 2021
201.14M
Average
118.63M
Median
Nov 03 2022
Enterprise Value Benchmarks
| AnaptysBio Inc | 298.25M |
| ABVC BioPharma Inc | 12.79M |
| Reviva Pharmaceuticals Holdings Inc | 55.36M |
| Flora Growth Corp | 13.82M |
| Journey Medical Corp | 58.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.06M |
| Revenue (Quarterly) | 113.72M |
| Total Expenses (Quarterly) | 70.57M |
| EPS Diluted (Quarterly) | 0.52 |
| Profit Margin (Quarterly) | 27.32% |
| Earnings Yield | -41.59% |
| Normalized Earnings Yield | -44.82 |